Compare
Gain Therapeutics, Inc. vs Emmaus Life Sciences, Inc. vs HCW Biologics Inc. vs Jyong Biotech Ltd.
| Latest fiscal year | Gain Therapeutics, Inc. GANX | Emmaus Life Sciences, Inc. EMMA | HCW Biologics Inc. HCWB | Jyong Biotech Ltd. MENS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $12.45M | $54.2K | n/a |
| Revenue growth (YoY) | n/a | -25.2% | -97.9% | n/a |
| Gross margin | n/a | 93.1% | 20.0% | n/a |
| Operating margin | n/a | 1.9% | n/m | n/a |
| Net margin | n/a | -60.2% | n/m | n/a |
| Net income | -$20.16M | -$7.49M | -$7.96M | -$4.67M |
| EPS (Diluted) | -$0.61 | -$0.12 | -$10.63 | -$0.06 |
| Operating cash flow | -$18.47M | -$11.0K | -$13.39M | -$3.04M |
| Free cash flow | n/a | -$12.0K | -$13.39M | n/a |
| Cash & equivalents | $20.84M | $2.13M | $1.95M | n/a |
| Total assets | $22.82M | $21.44M | $24.52M | $20.78M |
| Total liabilities | $4.25M | $85.04M | $21.76M | $45.68M |
| Shareholders' equity | $18.56M | -$63.61M | $2.76M | -$24.91M |
| Return on year-end equity | -108.6% | n/a | -287.9% | n/a |
| Shares outstanding | 42.07M | 70.19M | n/a | 76.03M |
Revenue, most recent five fiscal years
| Fiscal year | Gain Therapeutics, Inc. | Emmaus Life Sciences, Inc. | HCW Biologics Inc. | Jyong Biotech Ltd. |
|---|---|---|---|---|
| Latest | $55.2K Ended 2023-12-31 | $12.45M Ended 2025-12-31 | $54.2K Ended 2025-12-31 | n/a |
| 1 year earlier | $140.1K Ended 2022-12-31 | $16.65M Ended 2024-12-31 | $2.57M Ended 2024-12-31 | n/a |
| 2 years earlier | $165.0K Ended 2021-12-31 | $29.60M Ended 2023-12-31 | $2.84M Ended 2023-12-31 | n/a |
| 3 years earlier | $28.9K Ended 2020-12-31 | $18.39M Ended 2022-12-31 | $6.72M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $20.61M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a |